Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene Expression Analysis in HCV Genotype 1b Patients Treated with Peg-IFN + Ribavirin
NCT00680173Phase 4Completed
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Start
- Aug 2006
- Primary completion
- Mar 2016
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2a in hepatitis C (HCV) (2 arms), sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital. Primary endpoint: Sustained Virological Response at 1.5 year. Started Aug 2006; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00680173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00680173.